Uncommon Gynecologic Cancers

 

Description:

Rare gynecological cancers kill all too commonly

Gynecological cancer is a frightening prospect for women.

It is terrifying also for physicians who need, but often can’t find, guidance on how to investigate and appropriately treat the tumors.

Rare cancers provide greater challenges as information can be harder to find and more difficult to verify.

Rare Gynecologic Cancers: Diagnosis and Management brings together all you need to know on these life-threatening diseases.

Straightforward summaries of pathophysiologic processes lead to the investigations that will improve your diagnostic accuracy.

This provides the basis for you to identify effective treatment strategies for your patients.

Written by a world-leading team of Editors and Authors and covering cancers of the

•             Ovaries

•             Uterus

•             Vulva

•             Vagina

•             Cervix

Rare Gynecologic Cancers: Diagnosis and Management will guide you to the best life-saving treatment for your patients.

 

Table of Contents:

 

Part 1: General Principles

Chapter 1: Molecular Targets in Gynecologic Cancers

Introduction

Phosphoinositol 3-kinase (PI3K) pathway

Mitogen-activated protein kinase (MAPK) pathway

Human epidermal growth factor receptor 2 (HER2)

Vascular endothelial growth factor (VEGF)

Poly (adenosine) diphosphate [ADP]-ribose polymerase (PARP)

References

Chapter 2: Imaging of Rare Gynecologic Tumors

Imaging guidelines

Imaging of uncommon ovarian malignancies

Imaging of uncommon uterine and endometrial malignancies

Imaging of uncommon cervical malignancies

Imaging of uncommon vaginal and vulvar malignancies

Conclusion

References

Chapter 3: Pathology Overview of Rare Gynecologic Tumors

Ovary

The Uterine Corpus

Uterine Cervix

Vagina and Vulva

Fallopian Tube

Peritoneum

References

Part 2: Rare Ovarian Cancers

Chapter 4: Ovarian Clear Cell Carcinoma

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Future directions

Surveillance

Conclusions

References

Chapter 5: Mucinous Epithelial Ovarian Cancer

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Chapter 6: Pseudomyxoma Peritonei

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical Presentation

Pretreatment Evaluation

Treatment

Surveillance

Conclusions

References

Chapter 7: Squamous Cell Carcinoma of the Ovary

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Treatment

Survival

Surgical management

Fertility-sparing/conservative surgery

Chemotherapy

Radiation

Surveillance

Conclusions

References

Chapter 8: Endometriosis-Associated Ovarian Cancer

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

Conclusions

References

Chapter 9: Carcinosarcoma of the Ovary

Introduction

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Chapter 10: Malignant Germ Cell Tumors of the Ovary

Introduction

Epidemiology

Pathology

Immature teratoma

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Chapter 11: Malignant Sex Cord-Stromal Tumors of the Ovary

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Chapter 12: Small Cell and Neuroendocrine Cancers of the Ovary

Introduction

Small cell carcinoma

NSCNEC of the ovary

Conclusions

References

Chapter 13: Carcinoid Tumors of the Ovary

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

References

Part 3: Rare Uterine Cancers

Chapter 14: Uterine Carcinosarcoma

Epidemiology and presentation

Pathology

Pathogenesis

Surgical treatment

Adjuvant therapy

Choice of chemotherapy

What is the role of RT?

Treatment for recurrent disease

Prognosis

Surveillance

Conclusions

References

Chapter 15: Uterine Leiomyosarcoma

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Chapter 16: Mucinous Tumors of the Uterine Corpus

Introduction

Epidemiology

Pathology

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

Conclusions

References

Chapter 17: Uterine Clear Cell Carcinoma

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

Conclusions

References

Chapter 18: Updates on the Management of Uterine Serous Carcinoma

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

Conclusions

References

Chapter 19: Endometrial Stromal Sarcomas

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Surveillance

Conclusions

References

Part 4: Rare Cancers of the Cervix, Vulva and Vagina

Chapter 20 : Small Cell Neuroendocrine Carcinoma of the Cervix

Introduction

Epidemiology

Pathology

Clinical presentation

Pretreatment evaluation

Prognostic factors

Treatment

Conclusions

References

Chapter 21: Primary Malignant Melanoma of the Vagina and Vulva

Introduction

Epidemiology

Pathology

Pathogenesis

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

Prognosis

Conclusions

References

Chapter 22 : Sarcomas of the Vulva and Vagina

Introduction

Epidemiology

Pathology/pathogenesis

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

Conclusions

References

Chapter 23: Gestational Trophoblastic Disease

Introduction

Epidemiology

Pathogenesis

Pathology

Clinical presentation

Pretreatment evaluation

Treatment

Surveillance

Conclusions

References

Index

End User License Agreement